VCEL

Vericel Corp Ord
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$2.44B
P/E Ratio
111.19
EPS
$0.43
Beta
1.07
52W High
$48.75
52W Low
$28.95
50-Day MA
$38.81
200-Day MA
$36.56
Dividend Yield
Profit Margin
7.35%
Forward P/E
98.04
PEG Ratio
0.00

About Vericel Corp Ord

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$292.09M
Gross Profit (TTM)$218.59M
EBITDA$27.90M
Operating Margin-11.80%
Return on Equity6.59%
Return on Assets2.17%
Revenue/Share (TTM)$5.78
Book Value$6.98
Price-to-Book6.70
Price-to-Sales (TTM)8.36
EV/Revenue8.0
EV/EBITDA66.57
Quarterly Earnings Growth (YoY)18.90%
Quarterly Revenue Growth (YoY)30.10%
Shares Outstanding$51.07M
Float$50.44M
% Insiders1.19%
% Institutions113.68%

Historical Volatility

HV 10-Day
35.93%
HV 20-Day
39.89%
HV 30-Day
36.95%
HV 60-Day
43.98%
HV Rank
2.4%

Volatility is currently contracting

Analyst Ratings

Consensus ($55.43 target)
7
Buy
1
Hold

Latest News

Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026

BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second quarter 2026 financial results on Thursday, July 30, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

GlobeNewsWire7/16/2026Neutral
Vericel Q1 Earnings Call Highlights

Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.

MarketBeat5/9/2026Positive
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026

CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

GlobeNewsWire4/23/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VCEL and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/17/2026